Hepion Pharmaceuticals (NASDAQ:HEPA) Trading 8.8% Higher
Hepion Pharmaceuticals (NASDAQ:HEPA) Trading 8.8% Higher
Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA – Get Rating)'s share price traded up 8.8% during trading on Thursday . The company traded as high as $0.75 and last traded at $0.74. 312,151 shares were traded during trading, a decline of 58% from the average session volume of 736,713 shares. The stock had previously closed at $0.68.
Hepion Pharmicals, Inc.（纳斯达克股票代码：HEPA — Get Rating）的股价在周四的交易中上涨了8.8％。该公司的交易价格高达0.75美元，最后一次交易价格为0.74美元。交易期间交易了312,151股，较平均交易日交易量736,713股下降了58％。该股此前收于0.68美元。
Analysts Set New Price Targets
分析师设定了新的价格目标
A number of equities analysts have recently commented on the company. Brookline Capital Management reissued a "buy" rating on shares of Hepion Pharmaceuticals in a report on Tuesday, January 31st. Alliance Global Partners assumed coverage on Hepion Pharmaceuticals in a report on Monday, January 23rd. They set a "buy" rating for the company.
许多股票分析师最近对该公司发表了评论。布鲁克林资本管理公司在1月31日星期二的一份报告中重新发布了对Hepion Pharmicals股票的 “买入” 评级。Alliance Global Partners在1月23日星期一的一份报告中假设对Hepion P他们为公司设定了 “买入” 评级。
Hepion Pharmaceuticals Stock Performance
Hepion 制药股票表现
The company has a market cap of $59.19 million, a price-to-earnings ratio of -1.32 and a beta of 1.64. The business has a fifty day moving average price of $0.77 and a 200 day moving average price of $0.57.
该公司的市值为5,919万美元，市盈率为-1.32，beta为1.64。该公司的五十天移动平均价格为0.77美元，200天移动平均线价格为0.57美元。
Institutional Investors Weigh In On Hepion Pharmaceuticals
机构投资者对 Hepion Pharmicals 表示关注
A number of hedge funds and other institutional investors have recently bought and sold shares of HEPA. Renaissance Technologies LLC grew its position in Hepion Pharmaceuticals by 151.7% during the 1st quarter. Renaissance Technologies LLC now owns 126,600 shares of the company's stock worth $163,000 after acquiring an additional 76,300 shares during the last quarter. State Street Corp grew its position in Hepion Pharmaceuticals by 8.1% during the 1st quarter. State Street Corp now owns 348,910 shares of the company's stock worth $450,000 after acquiring an additional 26,194 shares during the last quarter. PVG Asset Management Corp bought a new stake in Hepion Pharmaceuticals during the 3rd quarter worth $55,000. Virtu Financial LLC grew its position in Hepion Pharmaceuticals by 195.6% during the 3rd quarter. Virtu Financial LLC now owns 67,802 shares of the company's stock worth $34,000 after acquiring an additional 44,867 shares during the last quarter. Finally, Envestnet Asset Management Inc. grew its position in Hepion Pharmaceuticals by 45.8% during the 3rd quarter. Envestnet Asset Management Inc. now owns 87,541 shares of the company's stock worth $44,000 after acquiring an additional 27,487 shares during the last quarter. Institutional investors own 9.37% of the company's stock.
一些对冲基金和其他机构投资者最近买入和卖出了HEPA的股票。Renaissance Technologies LLC在第一季度将其在Hepion Pharmicals的头Renaissance Technologies LLC在上个季度又收购了76,300股股票后，现在拥有该公司126,600股股票，价值16.3万美元。State Street Corp在第一季度将其在Hepion Pharmicals的头寸增长了8.1％。State Street Corp在上个季度又收购了26,194股股票后，现在拥有该公司价值45万美元的348,910股股票。PVG资产管理公司在第三季度收购了Hepion Pharmicals的新股份，价值55,000美元。Virtu Financial LLC在Hepion Pharmicals的头寸在第三季度增长了195.6％。Virtu Financial LLC在上个季度又收购了44,867股股票后，现在拥有该公司67,802股股票，价值34,000美元。最后，Envestnet资产管理公司在Hepion Pharmicals的头寸在第三季度增长了45.8％。Envestnet Asset Management Inc.在上个季度又收购了27,487股股票后，现在拥有该公司87,541股股票，价值44,000美元。机构投资者拥有该公司9.37％的股票。
About Hepion Pharmaceuticals
关于 Hepion 制药
(Get Rating)
（获取评级）
Hepion Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the development of drug therapy for treatment of chronic liver diseases. It focuses on the development of its product candidate CRV431, a cyclophilin inhibitor that targets biochemical pathways involved in the progression of liver disease.
Hepion Pharmicals, Inc是一家生物制药公司，从事治疗慢性肝病的药物疗法的开发。它专注于开发其候选产品 CRV431，这是一种靶向参与肝脏疾病进展的生化途径的亲环素抑制剂。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on Hepion Pharmaceuticals (HEPA)
- MarketBeat Week in Review – 3/27 – 3/31
- What is a Gold IRA, and is it a Viable Investment?
- Is Braze Inc Ready To Rocket Higher?
- Mullen Automotive Makes Deliveries; Short-Squeeze Possible
- Can Frontline Maintain This Momentum?
- 免费获取 StockNews.com 关于 Hepion Pharmicals（HEPA）的研究报告的副本
- MarketBeat Week 回顾 — 3 月 27 日 — 3 月 31 日
- 什么是黄金IRA，它是一种可行的投资吗？
- Braze Inc 准备好飞得更高了吗？
- Mullen Automotive 实现了交付；
- Frontline 能否保持这种势头？
Receive News & Ratings for Hepion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hepion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Hepion Pharmicals 每日新闻和评级 -在下面输入您的电子邮件地址，通过Marketbeat.com的免费每日电子邮件时事通讯接收Hepion Pharmicals及相关公司的最新新闻和分析师评级的简明每日摘要。
译文内容由第三方软件翻译。